# Integrated Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/integrated-diagnostics

- Industry: Healthcare
- Headquarters: Seattle, US
- Website: www.indidx.com
- Total disclosed funding: $134M
- Latest round: Series C (Dec 28, 2016)
- Investors on record: 7

## About

Integrated Diagnostics, Inc. specializes in advanced diagnostic solutions aimed at enhancing operational efficiency for healthcare providers. Their innovative products address critical challenges faced by professionals in the medical field.Founded in 2009 in Seattle, US, Integrated Diagnostics, Inc. focuses on developing technology solutions for the healthcare industry. In July 2018, the company was acquired by Biodesix, Inc. This acquisition reflects a strategic pivot in their business operations. The company has successfully completed a total of 8 deals, with the most recent funding round being Series C, which raised USD 6.1 mn led by Baird Capital Partners, bringing the total amount raised to USD 6.1 mn.Integrated Diagnostics, Inc. offers a comprehensive range of innovative diagnostic products and services aimed at enhancing efficiency for healthcare providers. Their core offerings include advanced technology solutions designed to streamline operations for both small and medium-sized enterprises (SMEs) and large healthcare organizations. These solutions target common challenges such as data management and operational bottlenecks, with a market presence across North America, Europe, and parts of Asia.The revenue model of Integrated Diagnostics, Inc. includes subscription-based services and direct-to-consumer sales. Clients engage with the company through structured agreements for access to their diagnostic solutions, ensuring ongoing support. The firm also collaborates with retailers and wholesalers to broaden their market reach. Their flagship products are strategically priced to capture value while catering to diverse customer segments, thereby promoting sustained customer engagement.Looking ahead, Integrated Diagnostics, Inc. is focused on launching new diagnostic products designed to expand their service offerings and meet evolving market needs. The company aims to penetrate additional markets in Europe and Asia by 2025. The recent funding from the Series C round will be utilized to support these initiatives, enhancing product development and market expansion efforts.

## Funding rounds

- Series C, Dec 28, 2016, $6.1M — Baird Capital Partners, InterWest Partners
- Series B, Apr 29, 2014, $30M — Baird Capital Partners, InterWest Partners, Wellcome Trust, Alexandria Venture Investments
- Series A, Feb 22, 2012, $10M — InterWest Partners, Wellcome Trust, Dievini, BioTechCube
- Series A, Jul 22, 2010, $10M — InterWest Partners, Wellcome Trust, Dievini, BioTechCube
- Series A, Sep 1, 2009, $78M — InterWest Partners, Wellcome Trust, Dievini, Accelerator Life Science Partners

## Investors

- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series A, Series B, Series C
- Wellcome Trust — Series A, Series B
- Dievini (https://capitalatlas.ai/funds/dievini) — Series A
- Accelerator Life Science Partners (https://capitalatlas.ai/funds/accelerator-life-science-partners) — Series A
- BioTechCube — Series A
- Baird Capital Partners (https://capitalatlas.ai/funds/baird-capital-partners) — Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B